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ImprintingEpigenetic changes refer to heritable changes that may modulate gene expression without affecting DNA
sequence. DNA methylation is one such heritable epigenetic change, which is causally associated with the
transcription regulationofmanygenes in themammalian genome. AlteredDNAmethylation has been implicated
in a wide variety of human diseases including cancer. Understanding the regulation of DNAmethylation is likely
to improve the ability to diagnose and treat these diseases.With the advent of high-throughput RNA interference
(RNAi) screens, answering epigenetic questions on a genomic scale is now possible. Two recent genome-wide
RNAi screens have addressed the regulation of DNA methylation in cancer, leading to the identiﬁcation of the
regulators of epigenetic silencing by oncogenic RAS and how epigenetic silencing of the tumor suppressor
RASSF1A is maintained. These RNAi screens have much wider applications, since similar screens can now be
adapted to identify the mechanism of silencing of any human disease-associated gene that is epigenetically
regulated. In this review,wediscuss two recent genome-wide RNAi screens for epigenetic regulators and explore
potential applications in understanding DNA methylation and gene expression regulation in mammalian cells.
Wealsodiscuss someof thekeyunansweredquestions in theﬁeld ofDNAmethylation and suggest genome-wide
RNAi screens designed to answer them.teins, polycomb group proteins;
istone acetyl transferase.
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Gene expression regulation plays an important role in almost
every aspect of an organism's life, including development, differen-tiation, and disease states. Regulation of gene expression may occur
by variety of mechanisms, including genetic and epigenetic changes
[1].While the former refers to the changes in the genetic code (change
in the DNA sequence), the latter is deﬁned as a heritable change in
which the sequence of the DNA remains unaltered. DNA methylation
is a form of epigenetic change in mammalian cells and will be the
focus of this review. In some instances, it also plays an important role
in the regulation of gene expression [2,3]. Multiple regulators of DNA
methylation have been identiﬁed, but despite intensive efforts, their
Fig. 1. Stochastic versus instructivemechanisms for epigenetic silencing.DNAmethylation
can be established by a stochasticmechanism inwhich cellswithmethylation of particular
genes will eventually outgrow cells lackingmethylation of growth inhibitory genes. In the
instructive model of epigenetic silencing, a signal transduction pathway or a genetic
change in the cells can regulate epigenetic silencing.
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regulation remains elusive [4]. In this review, wewill ﬁrst focus on the
current state of understanding about the process of DNA methylation
and demethylation and its proposed role in the regulation of gene
expression. Subsequently, we discuss two recent epigenomics-based
genome-wide RNA interference (RNAi) screens and show how these
screens resulted in the identiﬁcation of new pathways of epigenetic
regulation in cancer [2,3]. Finally, we suggest additional RNAi-based
methods to understand how DNA methylation regulates important
biological functions and utility of this information for improved
understanding of this epigenetic mark.
DNA methylation in mammalian cells
Since an epigenetic change does not affect the DNA sequence, it is in
principle reversible. DNA methylation is one such epigenetic change
that involves methylation of cytosine at position 5, usually in context of
CpG dinucleotides [4]. Non-CpGmethylation has been demonstrated in
mouse embryonic stem cells and recently, genome-wide bisulﬁte
sequencing of human stem cells has identiﬁed more extensive non-
CpG methylation in humans [5,6]. This non-CpG-associated DNA
methylation may be important for maintaining the pluripotent state
of stem cells, as differentiation of stem cells leads to a loss of non-CpG-
associated DNA methylation [6].
Proposed mechanisms for acquisition of DNA methylation
Cancer cells acquire both genetic and epigenetic changes that are
necessary for initiation, progression, and maintenance of tumor cells. It
is nowwell established that tumor cells may depend on speciﬁc genetic
changes for their survival, such as activated oncogenes. This phenom-
enon is referred to as “oncogene addiction.” Similar to genetic changes,
tumor cells also undergo epigenetic changes, such as changes in DNA
methylation that similar to genetic changes are required for tumor cell
survival [7,8]. These results indicate towards the existence of a state
similar to “oncogene addiction.” For example, somatic knockout of
both alleles of DNMT1 leads to apoptosis in HCT116 knockout cells [7,8].
This result may in part reﬂect on the requirement for the maintenance
of DNA methylation for the survival of HCT116 cells. Also, treatment
of various cancer cell lines with DNA demethylating agents such
as 5Aza2dC or Zebularin results in decreased DNA methylation and
reduced survival [9,10].
Mechanistically, at least two points of view exist regarding how
speciﬁc patterns of DNA methylation are acquired. The ﬁrst point of
view suggests that DNA methylation patterns are stochastically
generated and individual cells with a growth advantage are clonally
selected (Fig. 1). A second model invokes the existence of an
instructive mechanism of epigenetic silencing [11], wherein a signal
transduction pathway or a genetic changemay regulate the epigenetic
changes in a given cell type (Fig. 1). Support for the existence of an
instructive mechanism for epigenetic silencing is provided by two
recent genome-wide RNAi screens, which are described inmore depth
below [2,3].
Regulation of DNA methylation and demethylation
Mammalian DNA methylation is a dynamic process. Mammalian
DNA undergoes global changes in DNA methylation under various
circumstances, such as during development and tumorigenesis [4,12].
In this section of the review, we discuss the process of DNA
methylation and its possible role in regulation of gene expression.
The enzymatic activity that is required for de novo and mainte-
nance DNA methylation are called DNA methyltransferases (DNMTs).
DNMTs can add methyl groups at position 5 of cytosine on both
unmethylated or hemimethylated DNA. In mammalian cells, the
major DNMTs are DNMT1, DNMT3A, and DNMT3B [13–15]. DNMT3Aand DNMT3B can methylate unmethylated DNA and are thus referred
to as de novo DNA methyltransferases. DNMT1 can also methylate an
unmethylated substrate in vitro, but with much lower efﬁciency.
These ﬁndings suggest that DNMT1 primarily functions to maintain
DNAmethylation by preferentially methylating hemimethylated DNA
[16]. During every cycle of DNA replication, a new unmethylated
daughter strand of DNA is generated which is methylated by DNMT1.
Thus, these results suggest that DNMT1 activity is sufﬁcient to
maintain genomic DNA methylation (Fig. 2A). However, this is likely
to depend on cellular context as mouse embryonic stem cells (mES)
that lack Dnmt3a and Dnmt3b progressively lose DNA methylation
with each division, while mouse embryonic ﬁbroblast cells (MEFs)
that lack DNMT3A and DNMT3B are able to maintain DNA methyl-
ation [16]. Also, since DNMTs are not sequence-speciﬁc DNA binding
proteins, they need to be recruited to the DNA by other proteins to
methylate DNA. In some instances, polycomb group proteins (PcG)
and UHRF1 [ubiquitin-like, containing PHD and RING ﬁnger domains]
are required for the recruitment of DNMTs to DNA [17,18]. Recently, a
study indicated that PRE-like sequence elements that are bound by PcG
proteinsmaybepresent in human stemcells [19]. This study identiﬁed a
PRE-like D11.12 element between HOXD11 and HOXD12 genes.
Interestingly, this element had several highly conserved sequence
features, including a YY1 binding site, GC-rich sequence, and was
relatively nucleosome depleted [19]. In the future, it will be worth
investigating if this newly identiﬁed PRE-like element coincides with
polycomb recruitment and also how it correlateswith DNAmethylation
in a genome-wide analysis.
Similar to DNA methylation, DNA demethylation is also exten-
sively studied. Mechanistically DNA demethylation in mammalian
cells can be of two types [20]. The ﬁrst is dependent on DNA
replication and does not require any enzymatic activity and is called
passive DNA demethylation. The second form of DNA demethylation
that has been documented in the preimplantation stage, wherein
paternal genomic DNA undergoes a very rapid DNA demethylation in
the absence of any cell division [21] (Fig. 2B). A maternally deposited
factor with active DNA demethylase activity has been proposed to
account for this process. Interestingly, active DNA demethylation is
also invoked in cancer cells. For example, treatment of lung cancer cell
Fig. 2. Regulation of DNAmethylation and demethylation inmammalian cells and its role in regulation of gene expression. (A) In mammalian cells, DNA is methylated at CpG islands.
After replication, the DNA is initially hemimethylated. DNA methylation is maintained by DNMT1, while de novo methylation is performed by DNMT3A and DNMT3B. (B) Two
mechanisms for DNA demethylation are suggested; one that is DNA replication dependent and leads to replication-dependent loss of DNA methylation, while the other mechanism
evokes existence of an active DNA demethylase, which independent of DNA replication can reduce DNAmethylation. (C) Mechanisms for DNAmethylation-mediated transcriptional
gene silencing include one in which DNA methylation prevents binding of transcription activators and a second mechanism in which DNA methylation leads to recruitment of
corepressor complexes that eventually result in transcriptional repression.
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drug aphidicolin in combination with 5-Azadeoxycytidine (5Aza2dC)
results in reexpression of RASSF1A [2]. It is important to note that
level of reexpression for RASSF1A was lower when cell division was
inhibited, suggesting that efﬁcient demethylation in this system is
partly dependent on DNA replication [2]. Although multiple labs have
cloned and characterized various genes with “active DNA demethy-
lase” function, none of them seems to be universal [20] (Fig. 2B).
Repressive histone modiﬁcations and its relation to DNA methylation
and transcription regulation
Inmammalian cells, DNA is packed into chromatin. Nucleosomes are
the building blocks of chromatin and are typically an octamer composed
of two subunits of four types of histones: H2A, H2B, H3, and H4.
Nucleosomes and the linker histoneH1 facilitate higher order packingofthe DNA [22]. Chromatin can also be further classiﬁed into transcrip-
tionally active euchromatin regions or transcriptionally inactive
heterochromatin [23]. Many recent studies have identiﬁed histone
variants that in some instances are part of the nucleosome and can
substitute for either a core histone protein or the linker histone H1.
Although the understanding of the roles of histone variants is still at its
early stage, some studies such as the oneon aH2Ahistone variant, H2AZ
(H2AFZ), indicates that it is necessary for embryonic stem cell
differentiation. Interestingly H2AZ was bound to a different set of
genes in lineage-committed cells relative to embryonic stem cells,
indicating that its dynamic distribution may also be important for cell
fate transitions [24]. These results suggest that histone variants may
have highly deﬁned and speciﬁc function and allow cells to ﬁne-tune
their biological response. Other than histone variants, the core histone
proteins can be posttranslationally modiﬁed. This may affect formation
of heterochromatin, access of DNA binding factors to DNA and
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posttranslation modiﬁcations such as acetylation, methylation, phos-
phorylation, ubiquitination,ADP ribosylation, andbiotinylation. Someof
these changes have been shown to regulate gene expression and can be
either associated with transcriptional activation or repression. For this
review, we will focus on histone modiﬁcations that are associated with
transcriptional repression and might be directly relevant to DNA
methylation-mediated gene expression regulation. Among the most
common histone tail modiﬁcations that cause transcription repression
are histone deacetylation, methylation of histone H3 at lysine 9 and
trimethylation of histone H3 at lysine 27 [25]. Acetylation of lysine in
histone tails reduces the positive charge of histones and thus increases
the repulsion between histones and DNA, leading to a more open
chromatin structure and thus increased access for DNAbinding proteins
and increased transcription. Conversely, loss of histone acetylation leads
to a more compact histone–DNA complex and thus reduced transcrip-
tion. The enzymes responsible for acetylating histones are named
histone acetyl transferases (HATs), while the proteinswith that remove
acetyl groups from histone tails are called histone deacetylases
(HDACs). The second important modiﬁcation that is associated with
transcription repression is methylation of histone H3 at lysine 9 by
histone methyl transferases (HMTs) [25]. The most common HMTs are
SUV39H (SUV39H1) and G9A (EHMT2). Histone H3K9methylation has
dual roles. First, it represses transcription and second, this modiﬁcation
promotes recruitment of heterochromatin protein 1 (HP1, also known
as (CBX5)), which leads to spreading of the heterochromatin state [25].
In fact, there is evidence that H3K9 methylation in sufﬁcient for
establishing transcription repression. For example, targeted recruitment
of HMTusing zincﬁnger transcription factors can establish transcription
repression in vivo [26]. The third important histonemodiﬁcation that is
associated with transcription repression is H3K27methylation. Histone
H3 is modiﬁed at lysine 27 by the EZH2 histone methyltransferase,
which is the part of polycomb repressive complex 2 (PRC2). H3K27
trimethylation (H3K27triMe) is recognized by polycomb repressive
complex 1 (PRC1) and eventually leads to transcriptional silencing. It is
important to note that H3K9 methylation and H3K27 methylation can
be reversed by various histone demethylases in a manner analogous to
removal of histone acetylation by HDACs [27].
After understanding the different histone modiﬁcations that are
associated with “silent” chromatin now it is important to understand
repressive histone modiﬁcations in context of DNA methylation. Many
studies indicate that cross talk between DNA methylation and
repressive histonemodiﬁcations exist, although the order of the events
is not precisely understood. In general, increased DNA methylation is
associated with transcriptional gene repression [28], although in some
instances, a role for increased DNA methylation in gene activation has
been documented [29]. Many studies have suggested mechanisms for
DNA methylation-mediated transcriptional gene silencing. In certain
instances, DNA methylation of cytosine may hinder the binding of
transcriptional activators and thus prevent transcriptional activation
[30] (Fig. 2C; mechanism 1). However, more commonly, proteins that
speciﬁcally bind to methylated DNA recognize sequences with
methylated DNA. These proteins then recruit corepressor complexes,
which consequentially lead to transcriptional repression. MeCP2, which
is a DNA binding protein, binds to the methylated DNA by its methyl-
cytosine recognizing domain. This in turn can repress transcription
by recruiting a transcriptional repressor complex comprised of SIN3A
and histone deacetylase [31,32]. This transcriptional repression can
be reversed by treatment with histone deacetylase inhibitors, suggest-
ing that histone deacetylation is an essential component of DNA
methylation-mediated transcriptional gene silencing [28,31–33]
(Fig. 2C; mechanism 2). Moreover, studies using inhibitors of DNA
methylation and HDACs showed that DNA methylation and histone
modiﬁcations synergistically participate in gene expression regulation
[8]. For example, loss of SUV39H in embryonic stem cells leads to
decreased DNMT3B-dependent CpG methylation at major centromericsatellites and diminished histone H3K9 methylation, suggesting a link
between histone H3 methylation and DNAmethylation [34]. Similar to
H3 lysine 9 methylation, H3K27 methylation mark is also found to be
associatedwith regions of increasedDNAmethylation. For example, the
observation that polycomb group proteins are required for recruitment
of DNMTs might indicate that these two events are linked, although
this is not formally proven yet [17]. Interestingly, this relationship
between H3K27me3 and DNA methylation is not universal. A very
interesting studyusing amurine system found that promoters thatwere
marked by H3K27triMe in stem cells become frequently methylated
upon differentiation to lineage-committed neurons [35]. These ﬁndings
suggest a context-dependent interplay between PcG proteins and DNA
methylation [35].
Lessons from epigenetic-based genome-wide RNAi screens
So far, we have discussed the general biology and possible function
of DNAmethylation and how it is possible to regulate gene expression
in conjunction with various posttranslational histone modiﬁcations.
In this section of the review, we discuss two recently performed RNAi
screens that support the existence of an instructive mechanism of
epigenetic silencing. We also discuss how these epigenetic-based
RNAi screens have served as examples for similar screens that may
help us better understand the function and regulation of DNA
methylation in mammals and other organisms. Second-generation
lentiviral RNAi libraries are now available that make it possible to
perform screens in nondividing cells [36]. Also, now various types of
shRNA or siRNA-based libraries are available that allows the screens
to be performed in single shRNA/siRNA format or pooled format.
Identiﬁcation of factors required for RAS-mediated epigenetic silencing
RAS GTPases regulate multiple signaling pathways such as MAP
kinase, PI3Kinase, and RalGDS pathway [37]. RAS mutations are among
the most common genetic alterations and are found in over 30% of
human cancers. Activating mutations in RAS lead to deregulated
survival signaling and contribute to tumorigenesis [37]. A recent study
addressed a relatively unexplored aspect of RAS signaling, namely
epigenetic regulation by oncogenic RAS that had also been documented
previously [3,38,39]. These studies indicated that overexpression of
oncogenic RAS led to DNA methylation-directed transcription repres-
sion. These studies also indicated that RAS-mediated epigenetic
silencing may contribute to tumorigenesis. Thus, to understand the
epigenetic regulation by oncogenic RAS and identify the genes that are
necessary for RAS-mediated epigenetic silencing, the authors used
genome-wideRNAi screen. For this RNAi screen, a KRASNIH3T3 cell line
was used. The FAS gene is epigenetically silenced by promoter DNA
hypermethylation in KRAS NIH3T3 cells (Fig. 3A). The authors
hypothesized that if a gene is necessary for RAS-mediated epigenetic
silencing of FAS, knocking down the expression of such a regulatory
gene will lead to reexpression of FAS. To identify such genes, authors
infected KRAS NIH3T3 cells with 10 pools of shRNAs targeting over
28,000mouse genes. The cells that reexpressed FASwere puriﬁed using
magnetic beads. Genomic DNA was prepared, and the integrated
shRNAs were cloned and sequenced to identify the candidate genes
(Fig. 3B). The screen identiﬁed 28 gene products that were highly
diverse in their function, including DNA binding proteins, histone
modifying enzymes, kinases, and proteins regulating aging. The
identiﬁed candidates included members of PRC1, PRC2 as well as
DNMT1. Chromatin immunoprecipitation (ChIP) analysis showed that
at least 9 of the 28 factors were selectively recruited onto the FAS
promoter in KRAS NIH3T3 cells. This selective recruitment of the
proteins indicates that the binding of these repressive proteins
contributes to the epigenetic silencing. DNA methylation analysis
using either bisulﬁte sequencing or immunoprecipitation based mDIP
(methyl-cytosine ChIP) indicated that loss of any of these 28 genes lead
Fig. 3. RNAi screens identify regulators of RAS silencing and regulators of RASSF1A epigenetic silencing. (A) RAS can inhibit FAS by DNA methylation-directed transcriptional
repression. The components and mechanisms of this epigenetic repression were unknown. (B) Schematics of the genome-wide RNAi screen that lead to the identiﬁcation of genes
required for RAS-mediated epigenetic silencing of FAS and other genes that were epigenetically silenced by RAS. (C) Multiple epigenetic regulators are typically required for
promoter DNA methylation-mediated transcriptional repression. Studies that can identify such repressors on a global scale are of general importance. (D) Schematics of a genome-
wide RNAi screen that identiﬁed epigenetic regulators of RASSF1.
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methylation for FAS and reexpression of FAS protein [3]. Further studies
showed that many of these same 28 factors were required for the
maintenance of epigenetic silencing of several highly unrelated genes
thatwere epigenetically repressed by promoter DNA hypermethylation
similar to FASbyRAS [3]. Interestingly, a zincﬁngerproteinZFP354Bwas
found to be required for silencing of all the genes analyzed in this study.
Zinc ﬁnger proteins are KRAB domain containing transcription
repressors. Results showed that ZFP354B was posttranslationally
modiﬁed and targeted for proteosome-mediated degradation by RAS
signaling. Deletion of the PEST domain of the ZFP354B or use of PI3
kinase inhibitor LY294002 led to the stabilization of ZFP354B, suggest-
ing that activated PI3K signaling may be responsible for targeting
ZFP354B for degradation [3]. The necessity of this protein for RAS-
meditated epigenetic silencing suggests the existence of a cis-acting
element bound by ZFP354B in the promoter region of genes that are
targeted by oncogenic RAS by epigenetic silencing. Identifying such a
consensus DNA binding site for ZFP354B could allow for the iden-
tiﬁcation of genes that are possible targets for RAS-mediated epigeneticsilencing [3]. A study of kinetics for FAS gene repression showed that the
recruitment of these factors was highly cooperative (Palakurthy and
Green, unpublished data). In the future, it will be interesting to see if
these 28 factors constitute a pathway or multiple pathways that work
together to cause epigenetic silencing of RAS target genes. These
ﬁndings suggest that an instructivemechanism of DNAmethylation can
occur, as it appears that oncogenic RAS can dictate what genes will be
methylated in a manner that does not appear to be stochastic.
Identiﬁcation of epigenetic regulators of RASSF1A
Tumor suppressor genes can function as “guardian of genome,”
and loss of tumor suppressor genes by either genetic or epigenetic
mechanisms contributes to tumorigenesis [40]. Thus, methods that
can identify the epigenetic regulators of tumor suppressor silencing
will give important insights into the process of tumorigenesis. Such
studies will allow us to identify gene-speciﬁc epigenetic regulators,
which can then be targeted for selective reactivation of a given disease
associated gene, for example, a tumor suppressor in a cancer (Fig. 3C).
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the regulators of any epigenetically silenced gene. In an effort to
identify the epigenetic regulators of a frequently silenced tumor
suppressor gene RASSF1A, Palakurthy et al. performed a genome-
wide RNAi screen-based using human breast cancer cell line MDA-
MB-231. Authors utilized an innovative technique to set up this RNAi
screen. First, a 2-kbp promoter fragment of RASSF1A was cloned
upstream of Blasticidin–RFP fusion protein. This promoter–reporter
construct was then stably transfected in the breast cancer cell line
MDA-MB-231. The endogenous RASSF1A gene is epigenetically
silenced in MDA-MB-221 cells by promoter DNA hypermethylation.
After transfection, similar to the endogenous RASSF1A gene, the
RASSF1A promoter–reporter construct is epigenetically silenced. This
was conﬁrmed by the observation that treatment of these clones with
5Aza2dC leads to blasticidin resistance and reexpression of RFP. This
clone was then used to perform genome-wide RNAi screen using a
library that targeted ~28,000 genes (Fig. 3D). The screen identiﬁed
11 candidate genes that affected both tumorigenesis and RASSF1A
expression. Authors characterized HOXB3 from this study. HOXB3
was previously known to be associated with oncogenesis but the
mechanism for its oncogenic function was elusive.
Knockdown of HOXB3 in multiple cancer cell lines that have
RASSF1A epigenetically silenced by promoter DNA hypermethylation
lead to reexpression of RASSF1A. Measurement of various DNMT
transcript levels indicates that loss of HOXB3 express leads to
decreased DNMT3B expression and reduced recruitment of DNMT3B
on RASSF1A promoter, indicating that HOXB3 may transcriptionally
repress RASSF1A, in part, by recruitment of DNMT3B to the RASSF1A
promoter. ChIP experiments indicated that HOXB3 was recruited on
DNMT3B promoter and likely required for transcriptional activation of
DNMT3B promoter. Also, ectopic expression of HOXB3 in a cell line
that expresses RASSF1A increased the expression of DNMT3B and
eventually led to decreased RASSF1A expression. These results
indicate that HOXB3 is both necessary and sufﬁcient for induction of
epigenetic silencing of RASSF1A. Interestingly, further analysis
showed that PcG protein EZH2 was required for the recruitment of
DNMT3B on RASSF1A promoter. Coimmunoprecipitation and ChIP
studies showed that EZH2 interacts with DNMT3B and MYC. RNAi
experiments showed that both EZH2 and MYC were required for
RASSF1A epigenetic silencing. Additional studies using human non-
small cell lung cancer (NSCLC) tumor samples demonstrated that 60%
of lung adenocarcinoma with epigenetically silenced RASSF1A also
showed overexpression of both HOXB3 and DNMT3B, suggesting that
the in vitro results are also clinically relevant.
Future applications of genome-wide RNA interference screens to
identify regulators of DNA methylation
RNAi screens have revolutionized thewaywe study and understand
mammalian genetics. The examples of genome-wide RNAi screens
discussed abovedemonstrate how regulators of epigenetic silencing can
be identiﬁed on a global scale. To provide further examples of how
epigenetic changes and their regulation can be understood using such
screens,wepropose two screens, successful executionofwhichwill lead
to identiﬁcation of important regulators of imprinting.
RNAi screen to identify the regulators of imprinting
Imprinting is the silencing of genes in a parent-of-origin speciﬁc
manner. Defects in genomic imprinting are associated with multiple
human diseases, including cancer. For example, loss of IGF2R imprinting
has shown to be associatedwith colon cancer [41]. A studybyHolmet al.
used imprinting-free mouse embryonic stem cells. First, the authors
generated these cells by conditionally knocking outDNMT1 inmouse ES
cells, which led to genome-wide loss of DNA methylation, including
genomic imprinting. The authors then reactivated expression ofDNMT1, which led to re-establishment of global DNA methylation, but
reactivation of DNMT1did not result inmethylation of imprinted genes.
Authors referred to these ES cells as imprinting-free ES cells (IF-ES cells)
[42]. Mouse ﬁbroblast cells derived from these ES cells, were also
imprinting free (IF-MEF cells). These cells showed lower levels of tumor
suppressor genes p19 (Cdkn2a) and p53 (Trp53). Also IF-MEFs
spontaneously immortalized and characteristics of immortalization
and cooperated with oncogenic RAS to undergo transformation. While
the mouse embryonic cells that had intact imprinting did not form
tumors in the context of expression of oncogenic RAS. These results
suggested that imprinting can be a tumor-suppressive mechanism.
These IF-MEFs could also be very useful in understanding the
mechanism of imprinting using genome-wide RNAi screens. For
example, these cells could be used in a HSV-TK-based RNAi screen to
identify the activators of any imprinted gene (Fig. 4A). For example, the
promoter of an imprinted gene, such as, IGF2, can be cloned upstream to
a HSV-TK and after introduction of RNAi library and then selected on
Ganciclovir. The surviving colonies will indicate loss of gene expression
of regulators of imprinting. Similar screen may be performed in a colon
cancer cell line with IGF2 loss of imprinting. Although either system
could beutilized, the IF-MEFsmay lack other cancer-associated complex
genetic and epigenetic changes and thus likely represent a simpler
system to study the regulation of imprinting.
Synthetic lethality screen in the context of an epigenetic change
Synthetic lethality refers to a state where cells carrying a genetic
defect in combination with a second genetic change leads to lethality
while either of these defects alone is not lethal [43]. Such screens were
initially donewith yeast, and nowwith the availability of RNAi libraries,
it has become possible to perform such screens in mammalian cells. In
fact, two such screens were performed recently to identify synthetic
lethal interactions that selectively kill cells harboring activating RAS
mutations [44,45]. It is important to note that similar screens can be
performed in the context of an epigenetic change and identify synthetic
lethal interaction that target a speciﬁc epigenetic change such as
promoter DNA methylation of p16 gene in cancer cells. For example, in
this screen, synthetic lethal interactions in cell lines that express p16
could be compared with lines in which p16 is epigenetically repressed
by promoter DNA methylation (Fig. 4B).
Conclusion
DNA methylation is an important epigenetic change associated
with tissue-speciﬁc gene expression, development, differentiation,
and a variety of human diseases [28]. In cancer, DNA methylation is
associated with transcriptional repression of speciﬁc tumor suppres-
sor and proapoptotic genes and possibly in activation of proto-
oncogenes [28]. In addition, DNAmethylation at repeat sequences and
at nonpromoter sites is implicated in the control of transposition and
meiotic recombination [28]. DNA methylation is essential for the
survival of a variety of cancer cell types and thus provides a promising
target for the treatment of cancer. Dependence of cancer cells on
epigenetic changes is analogous to cancer-associated genetic muta-
tions. Also, it is important to note that genetic changes can also
function, in part, by altering cellular epigenetic patterns [3]. The
recent discovery of induced pluripotent stem cells (iPS) favors the
model of instructive epigenetic silencing, wherein four deﬁned factors
(SOX2, KLF4, OCT4 (POU5F1), and MYC) can reprogram a mouse
embryonic ﬁbroblast to iPS cells [46]. This may also be relevant in case
of some cancers, where cancer stem cells are implicated in cancer
initiation and repopulation after surgical resection or chemotherapy.
The demonstration that a melanoma cell can be reprogrammed to
generate a viable mouse with nuclear transplantation indicates that
cancer has a strong epigenetic component that affects tumorigenesis,
tumor progression, and maintenance [47].
Fig. 4. Proposed RNAi screens to study imprinting or synthetic lethality in the context of an epigenetic change. (A) A proposed screen for identiﬁcation of genes that regulate
imprinting. This screen can be adapted to understand the regulation of any imprinted gene. (B) Synthetic lethality screens can be performed in the context of an epigenetic change.
The ﬁgure depicts the schematics of a proposed RNAi screen that aims to identify synthetic lethal interactions in the context of p16 promoter DNA hypermethylation.
197V. Muthusamy et al. / Genomics 96 (2010) 191–198Genome-wide RNAi screens represent a promising new technique
to identify key factors that regulate critical epigenetic changes in
human cancer as well as diseases wherein epigenetic changes play
important role. With the recent advances in the sequencing
technology and availability of the bar-coded shRNA libraries, “drop-
out” and “synthetic lethality” screens have become feasible. Such
screens can also be performed in the context of an epigenetic change
to decipher the possibility of targeting epigenetic changes similar to
genetic changes for variety of human diseases. The screens performed
by Gazin et al. and Palakurthy et al. lay the foundation for more of
similar screens [2,3]. These screens can also be adopted to understand
many different aspects of epigenetic silencing, including examples
that we suggested for imprinting and identifying the synthetic lethal
interaction in the context of an epigenetic change. In the future, it will
be interesting to adapt these RNAi screens into in vivo epigenetic
screens, which will allow assessment of tumor microenvironment on
regulation of DNA methylation and its role in tumorigenesis.
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